Eclipsys/Allscripts Merger
On June 9, 2010 Allscripts (Nasdaq: MDRX) and Eclipsys (Nasdaq: ECLP) announced a definitive agreement to merge in an all-stock transaction valued at approximately $1.3 billion.
Under terms of the merger agreement, Eclipsys stockholders will receive 1.2 shares of Allscripts for each share of Eclipsys, a 19 percent premium based on the June 8th closing price.
UBS, Barclays Capital and J.P. Morgan acted as financial advisors to Allscripts on the merger, and Blackstone and William Blair acted as financial advisors to the Audit Committee of Allscripts. Perella Weinberg Partners acted as financial advisor to Eclipsys. Credit Suisse acted as financial advisor to Misys.
The companies expect the merger to close in approximately four to six months.
View Older Stories
-
UPDATE: Deutsche Bank Upgrades Allscripts (MDRX) to Buy
-
KIPU Health Appoints Healthcare Industry Leader R. Andrew Eckert as Chairman of its Board of Directors
-
Elliott Management Nominates Independent, Highly Qualified Trustee Candidates to the Board of Public Storage
-
SOC Telemed and HCMC Announce Special Meeting Date and Identify New Director Nominees in Anticipation of Close of Business Combination
-
Allscripts (MDRX) Sells EPSi to Strata Decision for $365M
-
Strata Decision Technology to Acquire EPSi From Allscripts
-
Europe's Deenova Boosts International Expansion in Pharmacy Automation Market
-
Solutionreach Appoints Dan Simenc as Chief Revenue Officer
-
Clinical AI Leader Jvion Names Industry Veteran Jay Deady as Chief Executive Officer
-
Spok Holdings (SPOK) Announces Bobbie Byrne M.D. to Board
-
Spok Appoints Bobbie Byrne, M.D. to Board of Directors
-
OLAH Healthcare Technology welcomes Max Immelman as Senior Sales Executive
-
OLAH Healthcare Technology welcomes Max Immelman as Senior Sales Executive
-
The SSI Group Names Jay Colfer Chief Operating Officer
-
VIVUS (VVUS) Appoints Karen Ferrell and Edward A. Kangas to Board
-
VIVUS Adds Two New Members to the Board of Directors
-
VIVUS Adds Two New Members to the Board of Directors
-
Health Catalyst Expands Senior Team with Health System and Industry Veterans
-
Shaun Priest Joins Clearwave
-
Dr. Charles Tuchinda Named Hearst Health Executive Vice President
-
Qualidigm Announces New Chairman and Three New Members to Its Board of Directors
-
Orion Health Taps Allscripts Alumnus Terry Macaleer to Lead U.S. Market
-
Recondo Adds Two Senior Executives to Support Continued Growth
-
Influence Health Announces New Chief Financial Officer and Chief Technology Officer
-
Streamline Health® Appoints Shaun Priest In Newly Created Position Of Chief Growth Officer
-
Bruce Matter Joins Banyan Medical Systems as Executive Vice President of Sales
-
Recondo Technology Appoints New Chief Technology Officer, And Chief Client Officer
-
Recondo Technology Strengthens and Expands Business Development and Sales Leadership Team with Three Healthcare Technology Industry Veterans
-
QlikTech (QLIK) Names Tim MacCarrick as CFO
-
Allscripts (MDRX) Higher as First-Round Bidding Complete
-
UPDATE: Piper Says 'Challenges' Lowers Allscripts (MDRX) Takeover Value, Sees Bids at $14/Share
-
M*Modal (MODL) Appoints Mike Etue as EVP of Sales
-
Auriga Upgrades Allscripts-Misys Healthcare (MDRX) to Buy; All Aboard Allscripts (Again!)
-
FBR Capital Maintains a 'Market Perform' on Allscripts-Misys Healthcare (MDRX); 1Q11 Shows Solid Results While Bookings Pullback Does Raise Some Concern
-
Auriga Downgrades Allscripts-Misys Healthcare (MDRX) to Hold
-
FBR Capital Starts Allscripts-Misys Healthcare (MDRX) at Market Perform; Merged Healthcare IT Co. Has Strong Base, But Plenty of Work to Do
-
Barclays Maintains an 'Overweight' on Allscripts-Misys Healthcare (MDRX); Bookings Boost Highlights Q4, with Our 2011 Estimates Again Up-Ticked
-
Barclays Maintains an 'Overweight' on Allscripts-Misys Healthcare (MDRX); Tone Into 4Q: Focus on Eclipsys Growth, Progress on Merger Integration
-
UBS Reiterates a 'Buy' Allscripts-Misys Healthcare (MDRX); Refreshing HIT Company Valuations
-
Deutsche Bank Upgrades Allscripts-Misys Healthcare (MDRX) to Buy
-
Barclays Reinstates an 'Overweight' Rating on Allscripts Healthcare (MDRX); Just What the Doctor Could Order
-
Auriga Downgrades Quality Systems (QSII) to Hold
-
Auriga Maintains a 'Buy' Rating on Allscripts-Misys (MDRX); Updating Model to Reflect Eclipsys, Fiscal Year Change
-
Deutsche Bank Reinstates Allscripts (MDRX) with a 'Hold'; ECLP Transaction May Yield Upside, But Valuation & Risks Balanced

